Preservative-free triamcinolone acetonide suspension developed for intravitreal injection

Journal of Ocular Pharmacology and Therapeutics

Volumn 24, Issue 1, 2008, Pages 62-69

  Bitter, Christoph ^a   Suter, Katja ^a   Figueiredo, Verena ^a   Pruente, Christian ^b   Hatz, Katja ^a   Surber, Christian ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG PRESERVATIVE; ENDOTOXIN; TRIAMCINOLONE ACETONIDE;

ARTICLE; CENTRIFUGATION; DRUG STABILITY; DRUG STERILITY; EVALUATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MEMBRANE FILTER; MICROSCOPY; PARTICLE SIZE; ROOM TEMPERATURE; SHELF LIFE; SPECTROMETRY; SUSPENSION;

ANTI-INFLAMMATORY AGENTS; CENTRIFUGATION; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRUG STABILITY; FILTRATION; INJECTIONS; PARTICLE SIZE; PRESERVATIVES, PHARMACEUTICAL; STERILIZATION; SUSPENSIONS; TRIAMCINOLONE ACETONIDE; VEHICLES; VITREOUS BODY;

EID: 38549109463     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2007.0043     Document Type: Article

References (53)

1. Peyman, G.A., and Moshfeghi, D.M. Intravitreal triamcinolone acetonide. Retina 24:488-490, 2004.
2. Gillies, M.C., Simpson, J.M., Billson, F.A., et al. Safety of an intravitreal injection of triamcinolone: Results from a randomized, clinical trial. Arch. Ophthalmol. 122:336-340, 2004.
3. Jonas, J.B. Intravitreal triamcinolone acetonide: A change in a paradigm. Ophthalmic Res. 38:218-245, 2006.
4. Jonas, J.B., and Sofker, A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am. J. Ophthalmol. 132:425-427, 2001.
5. Martidis, A., Duker, J.S., Greenberg, P.B., et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920-927, 2002.
6. Penfold, P.L., Gyory, J.F., Hunyor, A.B., et al. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust N. Z. J. Ophthalmol. 23:293-298, 1995.
7. Challa, J.K., Gillies, M.C., Penfold, P.L., et al. Exudative macular degeneration and intravitreal triamcinolone: 18-month follow-up. Aust. N. Z. J. Ophthalmol. 26:277-281, 1998.
8. Danis, R.P., Ciulla, T.A., Pratt, L.M., et al. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20:244-250, 2000.
9. Gillies, M.C., Simpson, J.M., Luo, W., et al. A randomized, clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: One-year results. Arch. Ophthalmol. 121:667-673, 2003.
10. Young, S., Larkin, G., Branley, M., et al. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin. Exp. Ophthalmol. 29:2-6, 2001.
11. Greenberg, P.B., Martidis, A., Rogers, A.H., et al. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br. J. Ophthalmol. 86:247-248, 2002.
12. Ip, M.S., and Kumar, K.S. Intravitreous triamcinolone acetonide as treatment for macular edema from central retinal vein occlusion. Arch. Ophthalmol. 120: 1217-1219, 2002.
13. Westfall, A.C., Osborn, A., Kuhl, D., et al. Acute endophthalmitis incidence: Intravitreal triamcinolone. Arch. Ophthalmol. 123:1075-1077, 2005.
14. Sutter, F.K.P., and Gillies, M.C. Pseudoendophthalmitis after intravitreal injection of triamcinolone. Br. J. Ophthalmol. 87:972-974, 2003.
15. Jaissle, G.B., Szurman, P., and Bartz-Schmidt, K.U. [Ocular side-effects and complications of intravitreal triamcinolone acetonide injection]. Ophthalmologe 101:121-128, 2004.
16. Nelson, M.L., Tennant, M.T.S., Sivalingam, A., et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 23:686-691, 2003.
17. Roth, D.B., Chieh, J., Spirn, M.J., et al. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch. Ophthalmol. 121:1279-1282, 2003.
18. Carrero, J.L., Flores, I.P., and Barcia, M.G. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am. J. Ophthalmol. 142:529-529, 2006.
19. Thompson, J.T. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am. J. Ophthalmol. 141:629-637, 2006.
20. Moshfeghi, D.M., Kaiser, P.K., Scott, I.U., et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am. J. Ophthalmol. 136:791-796, 2003.
21. Kivilcim, M., Peyman, G.A., El-Dessouky, E.S., et al. Retinal toxicity of triamcinolone acetonide in silicone-filled eyes. Ophthalmic Surg. Lasers 31:474-478, 2000.
22. Yeung, C.K., Chan, K.P., Chiang, S.W., et al. The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone. Invest. Ophthalmol. Vis. Sci. 44:5293-5300, 2003.
23. Yeung, C.K., Chan, K.P., Chan, C.K., et al. Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: Comparison with dexamethasone and hydrocortisone. Jpn. J. Ophthalmol. 48: 236-242, 2004.
24. McCuen, B.W., II, Bessler, M., Tano, Y., et al. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am. J. Ophthalmol. 91:785-788, 1981.
25. Hida, T., Chandler, D., Arena, J.E., et al. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am. J. Ophthalmol. 101:190-195, 1986.
26. Macky, T.A., Helmy, D., and El Shazly, N. Retinal toxicity of triamcinolone's vehicle (benzyl alcohol): An electrophysiologic and electron microscopic study. Graefe's Arch. Clin. Exp. Ophthalmol. 245:817-824, 2007.
27. Morrison, V.L., Koh, H.J., Cheng, L., et al. Intravitreal toxicity of the kenalog vehicle (benzyl alcohol) in rabbits. Retina 26:339-344, 2006.
28. Kai, W., Yanrong, J., and Xiaoxin, L. Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase of lens density. Graefe's Arch. Clin. Exp. Ophthalmol. 244:1152-1159, 2006.
29. Chin, H.S., Kim, T.H., Moon, Y.S., et al. A convenient method to concentrate triamcinolone acetonide for intravitreal injection. Retina 25:1107-1108, 2005.
30. Nishimura, A., Kobayashi, A., Segawa, Y., et al. Isolating triamcinolone acetonide particles for intravitreal use with a porous membrane filter. Retina 23:777-779, 2003.
31. Hernaez-Ortega, M.C., and Soto-Pedre, E. A simple and rapid method for purification of triamcinolone acetonide suspension for intravitreal injection. Ophthalmic Surg. Lasers Imaging 35:350-351, 2004.
32. Garcia-Arumi, J., Boixadera, A., Giralt, J., et al. Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use. Br. J. Ophthalmol. 89:1112-1114, 2005.
33. Rodriguez-Coleman, H., Yuan, P., Kim, H., et al. Intravitreal injection of triamcinolone for diffuse macular edema. Arch. Ophthalmol. 122:1085-1086, 2004.
34. Spandau, U.H., Derse, M., Schmitz-Valckenberg, P., et al. Triamcinolone acetonide concentration after filtration of the solvent agent. Am. J. Ophthalmol. 139: 712-713, 2005.
35. Sutter, F.K.P., Simpson, J.M., and Gillies, M.C. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: Three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled, clinical trial. Ophthalmology 111:2044-2049, 2004.
36. Jonas, J.B., Hayler, J.K., Sofker, A., et al. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am. J. Ophthalmol. 131:468-471, 2001.
37. Beer, P.M., Bakri, S.J., Singh, R.J., et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 110:681-686, 2003.
38. Jonas, J.B., Kreissig, I., and Degenring, R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br. J. Ophthalmol. 87:24-27, 2003.
39. Jonas, J.B., Kreissig, I., Sofker, A., et al. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch. Ophthalmol. 121:57-61, 2003.
40. Jonas, J.B., Kreissig, I., Hugger, P., et al. Intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Br. J. Ophthalmol. 87:462-468, 2003.
41. Jonas, J.B., Akkoyun, I., Budde, W.M., et al. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch. Ophthalmol. 122: 218-222, 2004.
42. Jonas, J.B., Degenring, R., Kreissig, I., et al. Safety of intravitreal high-dose reinjections of triamcinolone acetonide. Am. J. Ophthalmol. 138:1054-1055, 2004.
43. Klais, C.M., and Spaide, R.F. Intravitreal triamcinolone acetonide injection in ocular ischemic syndrome. Retina 24:459-461, 2004.
44. Massin, P., Audren, F., Haouchine, B., et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: Preliminary results of a prospective, controlled trial. Ophthalmology 111:218-224; discussion 224-215, 2004.
45. Moshfeghi, A.A., Scott, I.U., Flynn, J.H.W., et al. Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am. J. Ophthalmol. 138:489-492, 2004.
46. Chieh, J.J., Roth, D.B., Liu, M., et al. Intravitreal triamcinolone acetonide for diabetic macular edema. Retina 25:828-834, 2005.
47. Jonas, J.B., Akkoyun, I., Kreissig, I., et al. Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: A comparative, non-randomised study. Br. J. Ophthalmol. 89:321-326, 2005.
48. Jonas, J.B., Kreissig, I., Spandau, U.H., et al. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am. J. Ophthalmol. 141:579-580, 2006.
49. Quiram, P.A., Gonzales, C.R., and Schwartz, S.D. Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide. Am. J. Ophthalmol. 141:580-582, 2006.
50. Florey, K. Triamcinolone acetonide. Anal. Prof. Drug Subst. 1:397-421, 1972.
51. ICH Guidance for Industry Q3B(R2) Impurities in new drug products. International Conference on Harmonisation. 2006. http://www.ich.org/LOB/ media/MEDIA421.pdf Final version, July 2006 available at http://www.fda.gov/ cloer/gdlns/ich03br.pdf.
52. Robinson, M.R., Kim, H., Gravlin, L., et al. Preclinical evaluation of a triamcinolone acetonide preservative free (TAC-PF) formulation for intravitreal injection. Invest. Ophthalmol. Vis. Sci. 45:ARVO E-abstract 5058, 2004.
53. Kuppermann, B.D., Blumenkranz, M.S., Haller, J.A., et al. Randomized, controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch. Ophthalmol. 125: 309-317, 2007.